Clinical Efficacy of a Virtual Reality Tool for the Treatment of Obesity
NCT05094557 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96
Last updated 2022-05-05
Summary
The objective of the study, which is framed within European Union's H2020 project titled SOCRATES, is to assess the clinical efficacy of a Virtual Reality (VR) embodiment tool for treating obesity and to compare it to usual care, through a Randomized Controlled Trial
Conditions
- Obesity, Morbid
Interventions
- BEHAVIORAL
-
Experimental Group 1: Body swapping VR intervention + psychoeducational video + Treatment As usual
The patient will be embodied in his/her own avatar and will maintain a conversation with a counsellor's avatar of his/her choice. Once the experiment starts, the patient, embodied in his/her own body, will start describing his/her problem in terms of subjective experiences of being obese in daily life. Then, he/she will be body swapped to the counsellor's body and try to respond to the problem just manifested by the patient. The crucial aspect here is that the patient, from the counsellor's viewpoint, will see a representation of his/her real body when looking at the patient's avatar speaking and moving. Therefore, the patient will have the opportunity to see himself/herself in first person (1PP) and second person (2PP) perspectives.
- BEHAVIORAL
-
Experimental Group 2: VR intervention without body swapping + psychoeducational video + Treatment As usual
Participants from the Experimental Group 2 will be embodied in their own body and will participate in "pre-established discourse" provided by the chosen counsellor, who will ask about the perceived barriers for engagement with a healthier lifestyle and will give practical recommendations about how to achieve a healthier and happier life, in terms of healthy eating and physical activity. No body swapping will take place for this group. Participants will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle.
- BEHAVIORAL
-
Control Group: Psychoeducational video + Treatment As usual
Participants from the Control Group will receive their Treatment As Usual plus a Psychoeducational video. Treatment as usual will consist of regular medical, nutritional and/or psychiatric follow-ups with the obesity specialists of the Vall d´ Hebron University Hospital and standard routine tests. These visits aim to provide practical recommendations about how to achieve a gradual weight loss and engage more with physical exercise.
Sponsors & Collaborators
- collaborator OTHER
-
Hospital Universitari Vall d'Hebron Research Institute
lead OTHER
Principal Investigators
-
Pilar Lusilla-Palacios, MD, PhD · Vall d'Hebron University Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-01-31
- Primary Completion
- 2022-10-31
- Completion
- 2022-10-31
Countries
- Spain
Study Locations
More Related Trials
-
Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans
NCT02718950 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities
NCT04487743 ·Status: UNKNOWN ·Phase: PHASE3
-
A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.
NCT03560336 ·Status: COMPLETED
-
Effect Of Semaglutide In Coronary Atheroma Plaque
NCT05071417 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Effects of Liraglutide in Chronic Obstructive Pulmonary Disease
NCT03466021 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
NCT05035095 ·Status: COMPLETED ·Phase: PHASE3
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956 ·Status: RECRUITING ·Phase: PHASE2
-
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
NCT00796367 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
NCT06501326 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
NCT05051579 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
NCT04605861 ·Status: COMPLETED ·Phase: PHASE3
-
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
NCT00553787 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Litramine on Fat Excretion
NCT01590667 ·Status: COMPLETED ·Phase: PHASE4
-
Saxenda: Underlying Mechanisms and Clinical Outcomes
NCT02944500 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
3mg Liraglutide for Overweight or Obesity
NCT03885297 ·Status: COMPLETED
-
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06124807 ·Status: COMPLETED ·Phase: PHASE2
-
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
NCT02963935 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity
NCT06352437 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
NCT00422058 ·Status: COMPLETED ·Phase: PHASE2
-
Sodium Tungstate in Obesity
NCT00555074 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
NCT07150975 ·Status: RECRUITING ·Phase: PHASE3
-
A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity
NCT06577766 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
NCT07184632 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
NCT04707313 ·Status: COMPLETED ·Phase: PHASE2